

Rec'd PGT/PTO 14 JAN 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007501 A1

(51) International Patent Classification⁷: C07D 487/04,
A61K 31/407, A61P 19/00, 35/00

(21) International Application Number:
PCT/GB2003/002957

(22) International Filing Date: 15 July 2003 (15.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0216525.6 16 July 2002 (16.07.2002) GB
0217239.3 25 July 2002 (25.07.2002) GB
60/418,524 15 October 2002 (15.10.2002) US

(71) Applicant (for all designated States except US): AMURA
THERAPEUTICS LIMITED [GB/GB]; Incenta House,
Horizon Park, Barton Road, Cambridge CB3 7AJ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): QUIBELL, Martin
[GB/GB]; c/o Amura Therapeutics Limited, Incenta House,
Horizon Park, Barton Road, Cambridge CB3 7AJ (GB).
RAY, Peter, Christopher [GB/GB]; Roselea, Blairholyle,
Port of Monteith, By Kippen, FK8 3LF (GB). WATTS,
John Paul [GB/GB]; c/o Amura Therapeutics Limited, In-
centa House, Horizon Park, Barton Road, Cambridge CB3
7AJ (GB).

(74) Agents: SHEARD, Andrew, Gregory et al.; Andrew
Sheard, Patent Attorney, P.O. Box 521, Berkhamsted,
Hertfordshire, HP4 1YP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the fol-
lowing designations AE, AG, AL, AM, AT, AU, AZ, BA, BB,
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,
DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ,
TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

(54) Title: BIOLOGICALLY ACTIVE COMPOUNDS



(57) Abstract: Compounds of general formula (I) wherein: Z = CR³R⁴, where R³ and R⁴ are independently chosen from C₀₋₇-alkyl
P₁ = CR⁵R⁶, P₂ = O, CR⁷R⁸ or NR⁹, Y = CR¹⁰R¹¹-C(O) or CR¹⁰R¹¹-C(S) or CR¹⁰R¹¹-S(O) or CR¹⁰R¹¹-SO₂(X)₀₋₆=CR¹⁶R¹⁷ (W)₀=O, S,
C(O), S(O) or S(O)₂-or NR¹⁸ (V)_m=C(O), C(S), S(O), S(O)₂; S(O)₂NH, OC(O), NHC(O), NHS(O), NHS(O)₂, OC(O)NH, C(O)NH
or CR¹⁹R²⁰, C=N-C(O)-OR¹⁹ or C=N-C(O)-NHR¹⁹, U = a stable 5- to 7-membered monocyclic or a stable 8- to 11-membered
bicyclic ring which is either saturated or unsaturated, and which includes zero to four heteroatoms and their salts, hydrates, solvates,
complexes and prodrugs are inhibitors of cathepsin K and other cysteine protease inhibitors and are useful as therapeutic agents,
for example in osteoporosis, Paget's disease gingival diseases such as gingivitis and periodontitis, hypercalcaemia of malignancy,
metabolic bone disease, diseases involving matrix or cartilage degradation, in particular osteoarthritis and rheumatoid arthritis and
neoplastic diseases. The compounds are also useful for validating therapeutic target compounds.

WO 2004/007501 A1